Monthly Archives: January 2013

Home/2013/January

Understanding How GISTs Develop Enables Discovery of New Therapies

By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team   Researchers talk plainly about microGISTs, how this cancer develops and what all [...]

By |2019-09-20T13:22:48-04:00January 23rd, 2013|Clinical Trials, Diagnosis, GIST Education, Mutations, News, Research|

Imatinib Plasma Levels Revisited – An editorial post by Jerry Call

Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.

By |2019-04-08T09:01:29-04:00January 21st, 2013|Gleevec, News|

Phase II SARC-022 IGF-1R Trial Currently Recruiting and Planning to Add New Sites

The Sarcoma Alliance for Research through Collaboration (SARC) in partnership with the National Cancer Institute (NCI) is currently recruiting patients for its Phase II trial (SARC-022) of Linsitinib (OSI-906), an IGF-1R inhibitor. Linsitinib is targeted [...]

By |2019-09-20T13:23:36-04:00January 14th, 2013|Clinical Trials, News|

Sutent Treatment Use Trial Results

Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).

By |2019-09-20T13:24:08-04:00January 9th, 2013|Coping with GIST, News, Side Effects, Sutent|

LRG Survey Seeks to Understand Differences in Sutent Dosage Schedules

The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.

By |2019-09-20T13:24:43-04:00January 9th, 2013|News, Sutent|
Go to Top